Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Soumya D. Chakravarty"'
Autor:
Jessica A. Walsh, Iris Lin, Ruizhi Zhao, Natalie J. Shiff, Laura Morrison, Bruno Emond, Louise H. Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D. Chakravarty, Philip Mease
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 3, Pp 487-499 (2024)
Abstract Background Treatment persistence among patients with psoriatic arthritis (PsA) is essential for achieving optimal treatment outcomes. Guselkumab, a fully human interleukin-23p19-subunit inhibitor, was approved by the United States (US) Food
Externí odkaz:
https://doaj.org/article/5984faa752c244f89c78d0606e965338
Autor:
Stefan Siebert, Georg Schett, Siba P. Raychaudhuri, Monica Guma, Warner Chen, Sheng Gao, Soumya D. Chakravarty, Frederic Lavie, Proton Rahman
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 16 (2024)
Background: Guselkumab (human monoclonal antibody) selectively inhibits the interleukin (IL)-23p19 subunit. Objectives: Assess the longer-term pharmacodynamic effects of guselkumab and explore associations between such effects and clinical responses
Externí odkaz:
https://doaj.org/article/5fabba911e814e3b861bb0ca24ddd72f
Autor:
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice B. Gottlieb
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR; either inadequate efficacy
Externí odkaz:
https://doaj.org/article/8af8899c7fd64bf9a16ff7465d160dd3
Autor:
Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Ruizhi Sophia Zhao, Soumya D. Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 5, Pp 304-311 (2024)
Objective Evaluate patient‐reported outcomes after 6 months of on‐label guselkumab use in patients with rheumatologist‐diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry. Methods This analysis in
Externí odkaz:
https://doaj.org/article/197c05cdb19f4b9fb26fe2baaf5f58b3
Autor:
Laura C. Coates, Proton Rahman, Philip J. Mease, May Shawi, Emmanouil Rampakakis, Alexa P. Kollmeier, Xie L. Xu, Soumya D. Chakravarty, Iain B. McInnes, Lai-Shan Tam
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract Background To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab. Methods The Phase 3, random
Externí odkaz:
https://doaj.org/article/194d9d5826a142a58b96c1820ee7de94
Autor:
Philip J. Mease, Dafna D. Gladman, Denis Poddubnyy, Soumya D. Chakravarty, May Shawi, Alexa P. Kollmeier, Xie L. Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1637-1653 (2023)
Abstract Introduction Guselkumab previously showed greater improvements versus placebo in axial symptoms in patients with psoriatic arthritis (PsA) (assessed by Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Ankylosing Spondylitis Di
Externí odkaz:
https://doaj.org/article/78e3cd32eadf45c68aebb23a5cc1f2fa
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2859-2868 (2023)
Abstract Introduction The aim of this study was to evaluate guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis. Methods In the phase 3 VOYAGE-1 and -2 studies, at week
Externí odkaz:
https://doaj.org/article/5a5553774912446e94efd1f6ff6c66ad
Autor:
Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1479-1501 (2023)
Abstract Introduction The aim of this work is to evaluate treatment persistence and clinical outcomes after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/S
Externí odkaz:
https://doaj.org/article/670a15e0810945e28ecb889c8800099e
Autor:
Georg Schett, Warner Chen, Sheng Gao, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Miriam Zimmermann, Mohamed Sharaf, Laura C. Coates, Stefan Siebert
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-11 (2023)
Abstract Background Guselkumab is a selective interleukin (IL)-23 inhibitor targeting the IL-23p19 subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating participants with active psoriatic arthritis (PsA) and inadequate r
Externí odkaz:
https://doaj.org/article/dcfb8eb123704ee0a98a378fd8f4608d
Autor:
Laure Gossec, Elke Theander, Soumya D. Chakravarty, Paul Bergmans, Frederic Lavie, Wim Noël, Mohamed Sharaf, Stefan Siebert, Josef S. Smolen
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-9 (2023)
Abstract Background This post-hoc analysis of PsABio (NCT02627768) evaluated safety, effectiveness and treatment persistence in patients
Externí odkaz:
https://doaj.org/article/ea108c668aa748ff96589e82342b3aa6